Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. - Wikidata - wikimedia - TriplyDB

Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

http://www.wikidata.org/entity/Q36824801

about

Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis Novel epigenetic-based therapies useful in cardiovascular medicine Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction MicroRNAs; easy and potent targets in optimizing therapeutic methods in reparative angiogenesis Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration Adeno-associated virus-mediated gene therapy in cardiovascular disease miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways Over-expression of microRNA-1 causes arrhythmia by disturbing intracellular trafficking system.MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin Non-coding RNAs in cardiac hypertrophy.Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Circulating level of miR-378 predicts left ventricular hypertrophy in patients with aortic stenosis The myriad essential roles of microRNAs in cardiovascular homeostasis and disease.MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts.Differential expression of microRNAs in ischemic heart disease.Chronic Losartan Treatment Up-Regulates AT1R and Increases the Heart Vulnerability to Acute Onset of Ischemia and Reperfusion Injury in Male Rats.Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation.MicroRNAs in heart development.Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β.Crucial Role of miR-433 in Regulating Cardiac Fibrosis Atrial fibrillation and microRNAs.Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways The role of microRNAs in skin fibrosis.Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?MicroRNAs in heart failure: new targets in disease management.MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.MicroRNA in skeletal muscle development, growth, atrophy, and disease.Noncoding RNAs and myocardial fibrosis.Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease.Application of microRNAs in diagnosis and treatment of cardiovascular disease.MicroRNAs and atrial fibrillation: mechanisms and translational potential.Extracellular vesicles and atherosclerotic disease.Sexual dimorphisms of mRNA and miRNA in human/murine heart disease.Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?Evolving targeted therapies for right ventricular failure.

P2860

Q26746965-31113780-B0C4-4DF0-BB0E-B1B0590E3611 Q26765152-A54F77A5-3DD6-4F43-8903-22D1B9EB7BAE Q26771125-905B7096-18DB-4692-8969-159DD44442C6 Q26785405-884BBD2D-C6D8-4EA4-BEBC-02975B0071B6 Q26995349-5D32CDAC-D9B4-4AA4-9B1F-FF99AD53ECD3 Q28068468-2F56887A-2AB3-45CF-A59A-9C76E8B951B3 Q28081681-9219440A-41A5-4EC5-8100-F3678C4DC2F8 Q28544014-F882EBDF-6AA2-4BBA-A74D-53C94493BBF5 Q33551604-F0F86424-64B4-49F1-801A-E7DF76AF4513 Q33631076-2BB9D799-440A-43A8-BE95-39131BFE2D1C Q33800147-477CE492-0DC5-4D70-8396-A1629F3DC8D7 Q33821735-FE9C5C6B-3613-429D-964A-3030F458BD7A Q33902499-BC47D7FE-A951-4CAA-A844-99CB2DF39A77 Q34089884-1E8ADD95-F315-4EC1-8B38-BCD4943F3278 Q34356918-72B1A0D7-5C3B-4F79-83E2-B6EC22945DD1 Q34906347-7C89A796-C277-4C3B-A3DF-C29DF752034B Q35108100-7E55D028-9684-48E0-92FD-4343C7CB5CCC Q35689575-D5181F50-73B8-494A-850B-74C79B9FBECA Q36378208-C3644D58-9015-4F9C-903B-BAB1A233BB99 Q36518163-203C53E4-2B29-4FA2-8519-4A301F63B215 Q36955783-75BB7885-B75A-48A5-95E9-7EFD93FFE00E Q37037402-1DA1F79E-6536-4302-85C2-11091B3A2D87 Q37291267-AAC1AFE6-37F1-46D5-8D62-6EFEFD9ECE0B Q37511368-E1850593-4B12-4989-94B0-610DCE9E5096 Q37586770-F1AC9D81-2DF4-43E9-97DD-99D21299FCF4 Q37691772-D02B66B3-3B9E-40A5-BD76-FBB3B86FF3CE Q37696030-0556949C-D62D-4318-98A2-D31EBBC9F2E0 Q38118947-71EF6482-ADD9-48EB-9399-70A0A14B7FF7 Q38121484-D1A79DCD-4E67-4190-8EF6-B587288376F9 Q38161836-9D4A5EAD-56DE-422B-8B50-BE888D08E211 Q38212617-657F9113-B57D-40B4-B1E6-2CF772C945DB Q38247018-E282DA51-80E8-4A9C-916E-447999DCAB72 Q38254809-81ABDB2D-5D8D-4F5F-B6CF-3FAC742937A3 Q38264294-8A7CBB13-ED6D-4731-95EA-F212AB8D2BCA Q38271026-151B2C4F-3555-4812-9D9E-C342D757FB23 Q38430673-2941DE7A-63BC-428E-AF2F-7CE55319865E Q38431290-B3EFC0B3-B4B3-4934-ABD1-44AB2AB97905 Q38540889-C9A49D82-A778-4B27-9D3B-4A2B1E314B69 Q38555602-4E19881C-1437-49B0-8394-B065EE96C8FA Q38559308-0FBCE222-C388-41EA-B67B-9086B68C22C2

P2860

Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

http://www.wikidata.org/entity/Q36824801

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Therapeutic cardiac-targeted d ...... uates pathological remodeling.

@en

type

label

Therapeutic cardiac-targeted d ...... uates pathological remodeling.

@en

prefLabel

Therapeutic cardiac-targeted d ...... uates pathological remodeling.

@en

P1433

Q36824801-3F32A025-AC38-4CC3-ABEB-5C50096322A5

P1476

Q36824801-172BCB3B-AFF1-483B-89D3-A5B8ADC3E555

P2093

Q36824801-2AF186AC-C465-4E21-B3E2-6C25F8532A56

Q36824801-2F4578F6-66F7-4C0C-9CB2-A5DE2ABC5E46

Q36824801-43D79B55-4AF0-4DE2-B6AC-8678B013FFD3

Q36824801-6EA15147-9AB8-4779-93F8-37C24DAF4417

Q36824801-9414E157-1058-490F-80B8-986973F7A025

Q36824801-C7CA4D30-FD68-4FBA-80C9-8BE4BDF10617

Q36824801-D02578DF-D1BE-4E2F-8059-995EE68738C2

Q36824801-E2287086-4A11-4349-B384-6A4698EB6681

P2860

Q36824801-0170C14C-69C5-4DD0-A239-814D2DAF6150

Q36824801-06A8F7A9-1470-403B-843B-6E8ACE301150

Q36824801-08B35F6E-312B-4A30-8258-2BE5229A446F

Q36824801-112684AC-75C2-40C0-AB11-0C26803B3C1B

Q36824801-170A50A8-6947-4258-BD55-35BD53D44AB7

Q36824801-181CD836-2B9E-4669-8E8D-0D78117DBCD9

Q36824801-206C0822-2FD6-41A3-8905-DBCA011B274E

Q36824801-2674E3E5-A6DF-4541-82D7-ACA8CDF24962

Q36824801-2D455187-EEAC-4573-9828-3761E4AD73F6

Q36824801-2DD1C3B4-16D8-43B9-B91A-6BED388614F1

P304

Q36824801-5EAA7BDB-8A0A-4098-A47F-847461C729B8

P31

Q36824801-AFE873C5-069A-413D-9B8B-DF16F1CF2683

P356

Q36824801-6CCCA65C-7653-47D6-BC1A-F28742D28DF1

P433

Q36824801-D7910737-08B4-486F-A275-C6ADAB67C1DA

P478

Q36824801-9A539856-278D-48A6-9408-DA7D53EF2B07

P577

Q36824801-C3C0688D-AE38-436F-8D9B-98D8B043E7B0

P5875

Q36824801-6FFC6256-26A3-4AAF-8B06-D650BD8E886A

P698

Q36824801-C1418E3F-C02A-4454-9AC9-EC7D4C38D772

P932

Q36824801-42C41B37-6DF6-4D78-A6C9-C8707C22934E

P356

JAHA.113.000078

P1433

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

P1476

Therapeutic cardiac-targeted d ...... uates pathological remodeling.

@en

P2093

Antoine H Chaanine

http://www.w3.org/2001/XMLSchema#string

Bertrand N Mukete

http://www.w3.org/2001/XMLSchema#string

Djamel Lebeche

http://www.w3.org/2001/XMLSchema#string

Dongtak Jeong

http://www.w3.org/2001/XMLSchema#string

Ioannis Karakikes

http://www.w3.org/2001/XMLSchema#string

Roger J Hajjar

http://www.w3.org/2001/XMLSchema#string

Shihong Zhang

http://www.w3.org/2001/XMLSchema#string

Soojeong Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions

Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats

MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes

The microRNA.org resource: targets and expression

The impact of microRNAs on protein output

Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements

A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure

Mammalian microRNAs predominantly act to decrease target mRNA levels

Widespread changes in protein synthesis induced by microRNAs

Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs

P304

e000078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/JAHA.113.000078

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236276838

http://www.w3.org/2001/XMLSchema#string

P698

23612897

http://www.w3.org/2001/XMLSchema#string

P932

3647279

http://www.w3.org/2001/XMLSchema#string